Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia

European Journal of Clinical Investigation

Volumn 26, Issue 6, 1996, Pages 485-494

  Guerin M ^a   Bruckert, E ^a   Dolphin, P J ^b   Chapman, M J ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

High density lipoprotein; Lipoprotein subspecies; Very low density lipoprotein

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MALE; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0030002483     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.168318.x     Document Type: Article

References (22)

1. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apo B level in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res 1990;31:567-82.
2. Teng B, Sniderman AD, Soutar AK, Thomson GR. Metabolic basis of hyperapobetalipoproteinemia: turnover of apolipoprotein B and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986;77:663-72.
3. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993;34:295-308.
4. Janus EO, Nicoll AM, Turner PR et al. Kinetic bases of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest 1980;10:161-72.
5. Kissebah AH, Alfarsi S, Adamo PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism 1981;30:856-68.
6. Goldstein JL, Schrott GG, Hazzard WR et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-68.
7. Rose HG, Kranz P, Weinstock M et al. Inheritance of a combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am J Med 1983;54:148-60.
8. Chait A, Brunzell JD, Denke MA et al. Rationale of the Diet-Heart Statement of the American Heart Association Report of the Nutrition Committee. Circulation 1993;88:3008-29.
9. Tall AR. Plasma cholesteryl ester protein. J Lipid Res 1993;34:1255-71.
10. McPherson R, Mann CJ, Tall AR et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester protein activity and other lipoprotein variables. Arterioscler Thromb 1991;11:797-804.
11. Tato F, Vega GL, Tall AR, Grundy SM. Relation between cholesteryl ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995;15:112-20.
12. Guérin M, Dolphin PJ, Chapman MJ. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb 1994;14: 679-85.
13. Guérin M, Dolphin PJ, Chapman MJ. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apo B-containing lipoprotein subspecies. Identification of preferential cholesteryl esters acceptors in human plasma. Arterioscler Thromb 1994;14: 199-206.
14. Lagrost L, Gandjini H, Athias A et al. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb 1993;13:815-25.
15. Albers JJ, Chen CH, Lacko AG. Isolation, characterization and assay of lecithin: cholesterol acyltransferase. Methods Enzymol 1986;129:763-83.
16. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugation procedure for the isolation of the major lipoprotein classes from human plasma. J Lipid Res 1981;22:339-58.
17. Guérin M, Dolphin PJ, Talussot C, Gardette J, Berthezène F and Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arteroscler Thromb Vasc Biol 1995;15:1359-68.
18. Chapman MJ, Laplaud PM, Luc G et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. Lipid Res 1988;29: 442-58.
19. Lesnik P, Vonica A, Guérin M et al. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp (a). Arterioscler Thromb 1993;13:1066-75.
20. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991;88:2059-66.
21. Sata T, Havel RJ, Albers AL. Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipidemic and hyperlipidemic humans. J Lipid Res 1972;13:757-68.
22. Steinberg D, Parthasarathy S, Carew TE et al. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.